证券日报网讯2月13日，天士力（600535）在互动平台回答投资者提问时表示，公司目前经营正常，未 来公司将持续加强研发方面和销售方面的工作，努力提升企业价值。 ...

（文章来源：证券日报） 证券日报网讯 2月13日，天士力在互动平台回答投资者提问时表示，根据公司2025年度业绩快报，公司 归母净利润11亿元，同比增长15.68%。 ...

证券日报网讯 2月13日，天士力在互动平台回答投资者提问时表示，公司日常关联交易是公司生产经营 需要发生的日常经营性业务往来所需，以市场价格为基础协商定价，对公司持续经营能力、盈利能力等 不会产生不利影响。未来公司将持续加强研发和销售工作，努力提升公司价值。 （文章来源：证券日报） ...

证券日报网讯2月13日，天士力（600535）在互动平台回答投资者提问时表示，公司目前经营一切正 常，未来公司将持续加强研发工作以及销售工作，努力提升公司实际价值。 ...

近日，天士力宣布终止与美国Arbor公司的合作协议，双方原本共同推进的复方丹参滴丸（T89）美国市 场计划就此搁浅。尽管公司表示将收回相关权益并获750万美元款项，且"不会对生产经营产生重大影 响"，但这一事件仍折射出天士力在中药国际化、研发进展与企业经营等多层面所面临的风险与挑战。 复方丹参滴丸在美国的审批历程可谓一波三折。2017年，FDA要求该公司在已完成一项Ⅲ期试验的基础 上，再完成一项验证性临床试验，且两项试验均需达到统计学显著性（p＜0.05）。第一个试验耗时约 四年，第二个试验自2018年启动至今已超四年，结果仍未公布。 这种长时间、高投入的临床进程，不仅带来资金压力，也反映出中药复方在西方监管体系下面临的严谨 挑战。若第二次临床试验结果未达标准，多年努力恐将付诸东流。天士力在中药国际化领域的"孤军奋 战"局面——国内仅有极少数中成药尝试闯关FDA——也使其难以借鉴同行经验，试错成本高企。 三、公司经营困境与转型挑战 复方丹参滴丸的出海历程，某种程度上也映射了天士力近年来的发展轨迹。公司在2016–2019年间营收 一度逼近190亿元，但随后因出售营销子公司、受医保控费与集采政策影响，业绩持续承 ...

Core Viewpoint - Tianshili has terminated its collaboration with Arbor Pharmaceuticals, impacting the U.S. market expansion plan for its compound Danshen dripping pill (T89), which was a key project for the internationalization of traditional Chinese medicine [1][4]. Group 1: Collaboration Termination - The termination of the partnership with Arbor was due to Arbor's acquisition by Azurity and subsequent business adjustments, leading to the end of the U.S. market cooperation plan for T89 [1][4]. - Tianshili will receive a payment of $7.5 million as part of the termination agreement and will regain exclusive sales rights for T89 in the U.S. [1][4]. - The company stated that this termination will not significantly impact its project advancement, production operations, or financial status [1][4]. Group 2: Historical Context of T89 - The internationalization of T89 began in 1998 when it was officially approved for clinical research by the U.S. FDA [3]. - T89 received FDA approval for indications related to chronic stable angina and acute altitude sickness in 2006 and 2018, respectively [4]. - Tianshili and Arbor signed a licensing agreement in September 2018, with Arbor committing up to $23 million for research and obtaining exclusive sales rights for T89 in the U.S. [4]. Group 3: Clinical Trials and Regulatory Challenges - Tianshili has accumulated significant overseas clinical trial experience prior to the collaboration with Arbor, having completed a large-scale Phase III clinical trial [4][5]. - The success of T89's U.S. market entry hinges on obtaining regulatory approval based on clinical data, with the product still awaiting approval [5][6]. - Tianshili is currently conducting two Phase III clinical trials for T89, with the results of the second trial being crucial for U.S. approval [6][9]. Group 4: Company Performance and Market Position - Tianshili is a leading company in the modern Chinese medicine sector, listed on the Shanghai Stock Exchange since 2002 [7]. - T89 is Tianshili's most recognized product, achieving sales of over 3.3 billion yuan in 2015 and maintaining its position as the top-selling traditional Chinese medicine product for 13 consecutive years [8]. - The company has faced declining revenues since 2020, with total revenue of 8.236 billion yuan in 2025, a decrease of 3.08% year-on-year, and a net profit decline of 24.06% [11].

Investment Rating - The report maintains a "Buy" rating for key companies in the pharmaceutical sector, including Innovent Biologics, Efang Biologics, Tianshili, WuXi AppTec, and Mindray Medical [4][28]. Core Insights - The policy-driven upgrade of traditional Chinese medicine (TCM) industry is expected to enhance industry concentration in the medium to long term, benefiting companies with strong quality control and innovative capabilities [2][24]. - The implementation plan for high-quality development of the TCM industry aims to establish a collaborative development system by 2030, focusing on raw material supply, innovation, production quality control, and internationalization [2][23]. - The investment strategy emphasizes the importance of clinical value in the pharmaceutical sector, recommending a focus on innovative drugs and high-end medical devices [3][26]. Summary by Sections Market Review - The A-share pharmaceutical index rose by 0.14%, outperforming the CSI 300 index by 1.47 percentage points [1][16]. - The Hong Kong Hang Seng Medical Health Index fell by 1.41%, but still outperformed the Hang Seng Index by 1.65 percentage points [1][16]. Policy Insights - The Ministry of Industry and Information Technology and other departments issued a plan to enhance the TCM industry, which includes fostering leading enterprises and establishing high-standard raw material production bases [2][24]. - The plan emphasizes digitalization and sustainability, aiming to raise compliance standards and accelerate the exit of smaller companies from the market [2][25]. Company Updates - Recent clinical progress includes the NDA submission for HRS-9531 by Heng Rui Medicine and the initiation of clinical trials for various drugs by other companies [1][31][32]. - Key companies such as Yunnan Baiyao, Baiyunshan, and Taiji Group are highlighted for their strong positions in raw material supply [2][25]. Financial Forecasts - The report provides earnings per share (EPS) forecasts for key companies, with Innovent Biologics projected to have an EPS of 0.49 in 2025 and WuXi AppTec expected to reach an EPS of 5.07 in the same year [4][28]. - The pharmaceutical manufacturing industry reported a revenue decline of 1.2% year-on-year for 2025, with total revenue reaching 2,487 billion yuan [51].

Performance Highlights - Guomachine General reported a net profit of 585.16 million yuan for 2025, a year-on-year increase of 45.71% with total revenue of 899 million yuan, up 17.32% [5] - Tianshili achieved a net profit of 1.105 billion yuan, a 15.68% increase year-on-year, despite a revenue decline of 3.08% to 8.236 billion yuan [5] - Focus Technology's net profit rose by 11.73% to 504 million yuan, with total revenue reaching 1.92 billion yuan, up 15.06% [5] - Times Electric reported a net profit of 4.105 billion yuan, a 10.88% increase, with total revenue of 28.761 billion yuan, up 15.46% [5] - Tongxingbao's net profit increased by 5.51% to 221 million yuan, with total revenue of 1.068 billion yuan, up 19.24% [5] Capital Increase & Restructuring - Ruili Kemi is planning to issue shares to acquire a 16% stake in its subsidiary, with trading suspended from February 9 [6] - Longyun Co. intends to acquire a 58% stake in Yuheng Film and Television, with trading resuming on February 9 [6] - Yingwang Yingchuang is set to acquire 100% of Lianshi Legend, a smart marketing service provider [6] - Jiantou Energy's application for a specific stock issuance has been approved by the Shenzhen Stock Exchange [6] - Shanshan Co. signed a restructuring investment agreement with its controlling shareholder [6] Major Events - Aihuilong received a notice of investigation from the China Securities Regulatory Commission for suspected information disclosure violations [9] - Tiansheng New Materials also received a notice of investigation for similar reasons [10] - Cloud Road Co. announced the lifting of the detention of its chairman and general manager [10] - TCL Zhonghuan's subsidiary signed a patent licensing agreement with Aiyu Co. for a total fee of 1.65 billion yuan [11] - Shenjian Co. reported that its aerospace business revenue is relatively small, accounting for less than 1% of total revenue [11] Investment Projects - Wantong Expressway plans to invest approximately 5.42 billion yuan in the renovation and expansion of the Lianhuo Expressway [15] - Zhixin Co. intends to invest up to 1.1 billion yuan in an automotive welding parts project [15] - Hangyu Technology plans to invest up to 1.05 million euros in a forging production base in Slovakia [15] - Dongtianwei is set to invest 400 million yuan in a global R&D center and manufacturing headquarters in South China [15] - Zhongguancun is planning to build a modern digital factory for traditional Chinese medicine in Jiamusi City [15] Stock Trading Updates - The stock of Cuihua Jewelry will be suspended for one day starting February 9 due to the freezing of its main bank accounts [4] - The stock of Longyun Co. will resume trading on February 9 after a suspension [23] - Ruili Kemi and Yongtai Technology will be suspended from trading starting February 9 [24]

公告显示，2025年，公司正式成为华润三九（000999）旗下一员，以创新驱动开启融合发展新篇章，顺 利完成与华润三九的"百日融合"并稳步推动"首年融合"各项工作，在业务稳定、团队稳定、客户稳定基 础上，以"四个重塑"为指引，加快与华润三九的资源整合。面对医药行业集采控费等政策因素影响，公 司持续聚焦心血管及代谢、神经/精神、消化三大治疗领域，积极推进核心业务，全面提升企业效益、 效率和竞争力，坚持创新驱动，实现高质量发展，向"成为中国医药市场的领先企业"的目标稳步迈进。 (王珞) 天士力（600535）近日发布2025年度业绩快报，公司2025年实现归属于上市公司股东的净利润11.05亿 元，同比增长15.68%；公司基本每股收益0.74元，同比增长15.63%。 ...

提高投资者回报 研发管线潜在价值凸显 根据公司业绩快报，公司全年实现基本每股收益0.74元，同比增长15.63%，实现企业对投资者回报的提 高。 本报讯 （记者袁传玺）天士力2025年加入华润体系后首年融合业绩超出市场预期。2月6日晚间，天士 力发布的2025年业绩快报显示，公司2025年实现营业总收入82.36亿元；实现归属于上市公司股东的净 利润11.05亿元，同比增加15.68%。 融入华润体系推动提质增效 据悉，天士力作为华润三九"一体两翼"战略中的"一翼"，核心定位为"创新驱动"。天士力正全面推进与 华润三九的首年融合工作，从"价值重塑"、"业务重塑"、"组织重塑"和"精神重塑"四个维度系统化升级 管理体系，实现强强联合的战略协同。 公司在融入华润体系的同时，进行组织和运营管理等各个方面的优化，逐步提升公司经营资产的质量。 申万宏源证券的研报指出，华润三九将借助其在管理、渠道、产业方面的资源，为公司进一步赋能，促 进协同效应，提升天士力的竞争优势。在运营管理方面，公司积极落实华润管理理念，加强财务、人力 资源、EHSQ及大监督体系的融合，开展"焕新增效"等系列组织优化活动，优化运营管控模式，提升管 ...